China Biologic Products Honored with the Advanced Technology Certification for Foreign-Funded Enterprises
July 17 2008 - 8:00AM
PR Newswire (US)
TAIAN CITY, Shandong, China /Xinhua-PRNewswire-FirstCall/ -- China
Biologic Products, Inc. (OTC:CBPO) (BULLETIN BOARD: CBPO) (the
"Company"), one of the leading plasma-based pharmaceutical
companies in the People's Republic of China ("PRC"), today
announced that on July 8, 2008, the Company was awarded the
Advanced Technology Certification for Foreign Funded Enterprises
(the "Certification") from the Department of Foreign Trade and
Economic Cooperation of Shandong Province ("Shandong DOFTEC").
Shandong DOFTEC is a government-sponsored organization in charge of
foreign trade affairs and economic cooperation for Shandong
Province. The Certification was granted to the Company because the
Company met the strict requirements and standards set by Shandong
DOFTEC for high-tech foreign-funded companies. "It is an honor to
receive the Certification," said Mr. Chao Ming Zhao, the Company's
CEO. "We believe that the recognition from Shandong DOFTEC enhances
our competitive position and confirms our commitment to the
production of high-quality plasma-based products with advanced
technology." The Certification is renewable in three years, subject
to the Company's continued adherence to Shandong DOFTEC's
Certification standards. About China Biologic Products, Inc.
Through its indirect majority-owned subsidiary Shandong Taibang
Biological Products Co. Ltd., China Biologic Products, Inc. (the
"Company"), is principally engaged in the research, development,
production and sale of plasma-based biopharmaceutical products to
hospitals and other health care facilities in China. The Company's
human albumin products are mainly used to increase blood volume,
and its immunoglobulin products are used for the treatment and
prevention of diseases. Safe Harbor Statement This release may
contain certain "forward-looking statements" relating to the
business of China Biologic Products, Inc., and its subsidiary
companies. All statements, other than statements of historical fact
included herein, are "forward-looking statements," including
statements regarding the following: the significance of receiving
the Certification; the ability of the Company to achieve its
commercial objectives; the business strategy, plans and objectives
of the Company and its subsidiaries; and any other statements of
non- historical information. These forward-looking statements are
often identified by the use of forward-looking terminology such as
"believes," "expects" or similar expressions involving known and
unknown risks and uncertainties. Although the Company believes that
the expectations reflected in these forward-looking statements are
reasonable, they do involve assumptions, risks and uncertainties,
and these expectations may prove to be incorrect. Investors should
not place undue reliance on these forward-looking statements, which
speak only on and as of the date of this press release. The
Company's actual results could differ materially from those
anticipated in these forward-looking statements due to a variety of
factors, including those discussed in the Company's periodic
reports that are filed with the Securities and Exchange Commission
and available on its website (http://www.sec.gov/). All
forward-looking statements attributable to the Company or persons
acting on its behalf are expressly qualified in their entirety by
these factors. Other than as required under the securities laws,
the Company does not assume a duty to update these forward-looking
statements. For more information, please contact: Company Contact:
Mr. Y. Tristan Kuo CFO China Biologic Products, Inc. Tel:
+86-538-6202206 Email: Web: http://www.chinabiologic.com/ Investor
Relations Contact: Mr. Crocker Coulson President CCG Investor
Relations Tel: +1-646-213-1915 (NY office) Email: Web:
http://www.ccgir.com/ DATASOURCE: China Biologic Products, Inc.
CONTACT: Company Contact, Mr. Y. Tristan Kuo, CFO at China Biologic
Products, Inc., +86-538-6202206, or ; Investor Relations Contact,
Mr. Crocker Coulson, President of CCG Investor Relations,
+1-646-213-1915 (NY office), or , both for China Biologic Products,
Inc. Web site: http://www.chinabiologic.com/ http://www.ccgir.com/
Copyright